FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used for individual prediction of a fatal cardiovascular event (CVE). Patient is examined for amylin level, pancreatic polypeptide (PP) and tumour necrosis factor alpha (TNFa) in blood serum. If the amylin level increases above 10.5 pg/ml and/or PP exceeds 43.7 pg/ml, and/or the TNFa level drops below 3.8 pg/ml, a high risk of developing CVE is stated in young people.
EFFECT: method, being minimally invasive, enables to determine in young people the risk of developing CVE in 5-year period, it can be performed in a clinical biochemical laboratory, not depending on the changing conditions of real clinical practice, which in turn enables early prevention of cardiovascular diseases and reduce the level of disability of the working population.
1 cl, 3 dwg, 2 tbl, 4 ex
